Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass.

We investigated the effect of glucokinase activator (GKA) on glucose metabolism and beta-cell mass. We analyzed four mouse groups: wild-type mice and beta-cell-specific haploinsufficiency of glucokinase gene (Gck(+/-)) mice on a high-fat (HF) diet. Each genotype was also treated with GKA mixed in the HF diet. Rodent insulinoma cells and isolated islets were used to evaluate beta-cell proliferation by GKA. After 20 wk on the above diets, there were no differences in body weight, lipid profiles, and liver triglyceride content among the four groups. Glucose tolerance was improved shortly after the GKA treatment in both genotypes of mice. beta-Cell mass increased in wild-type mice compared with Gck(+/-) mice, but a further increase was not observed after the administration of GKA in both genotypes. Interestingly, GKA was able to up-regulate insulin receptor substrate-2 (Irs-2) expression in insulinoma cells and isolated islets. The administration of GKA increased 5-bromo-2-deoxyuridine (BrdU) incorporation in insulinoma cells, and 3 d administration of GKA markedly increased BrdU incorporation in mice treated with GKA in both genotypes, compared with those without GKA. In conclusion, GKA was able to chronically improve glucose metabolism for mice on the HF diet. Although chronic GKA administration failed to cause a further increase in beta-cell mass in vivo, GKA was able to increase beta cell proliferation in vitro and with a 3-d administration in vivo. This apparent discrepancy can be explained by a chronic reduction in ambient blood glucose levels by GKA treatment.

[1]  J. Gromada,et al.  A novel glucokinase activator modulates pancreatic islet and hepatocyte function. , 2005, Endocrinology.

[2]  S. R. Datta,et al.  Dual role of proapoptotic BAD in insulin secretion and beta cell survival , 2008, Nature Medicine.

[3]  C. Rhodes,et al.  Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells , 2004, Diabetologia.

[4]  S. Uemoto,et al.  GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. , 2008, Biochemical and biophysical research communications.

[5]  J. Sturis,et al.  Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.

[6]  T. Becker,et al.  Ventromedial Hypothalamic Glucokinase Is an Important Mediator of the Counterregulatory Response to Insulin-Induced Hypoglycemia , 2008, Diabetes.

[7]  C. Allott,et al.  Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats , 2006, British journal of pharmacology.

[8]  R. Pederson,et al.  Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. , 2002, Diabetes.

[9]  H. Aburatani,et al.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. , 2007, The Journal of clinical investigation.

[10]  H. Kasai,et al.  Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. , 1995, The Journal of biological chemistry.

[11]  R. M. Shepherd,et al.  Glucose-Dependent Modulation of Insulin Secretion and Intracellular Calcium Ions by GKA50, a Glucokinase Activator , 2007, Diabetes.

[12]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[13]  S. Bonner-Weir,et al.  A dominant role for glucose in β cell compensation of insulin resistance , 2007 .

[14]  R. Printz,et al.  Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions , 2007, Diabetologia.

[15]  A. Kadotani,et al.  An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism* , 2006, Journal of Biological Chemistry.

[16]  Yue Feng,et al.  Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes , 2006, Diabetes.

[17]  A. Baron,et al.  Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. , 2005, Endocrinology.

[18]  B. Glaser,et al.  Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. , 1998, Diabetes.

[19]  Christopher J. Rhodes,et al.  Type 2 Diabetes-a Matter of ß-Cell Life and Death? , 2005, Science.

[20]  G I Bell,et al.  Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. , 2001, The New England journal of medicine.

[21]  J. Grippo,et al.  Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. , 2001, Diabetes.

[22]  T. Noda,et al.  Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. , 2004, The Journal of clinical investigation.

[23]  S. Aizawa,et al.  Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. , 2000, Diabetes.

[24]  P. Froguel,et al.  Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families , 1997, Diabetologia.

[25]  Teruyuki Nishimura,et al.  Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.

[26]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[27]  F M Matschinsky,et al.  A Lesson in Metabolic Regulation Inspired by the Glucokinase Glucose Sensor Paradigm , 1996, Diabetes.

[28]  T. Kodama,et al.  Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease. , 1997, The Journal of clinical investigation.

[29]  P. Froguel,et al.  Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions , 2007, Nature Medicine.

[30]  J. Holst,et al.  Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. , 2002, European journal of endocrinology.

[31]  M. Prentki,et al.  Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells , 1999, Diabetologia.

[32]  M. Prentki,et al.  Islet beta cell failure in type 2 diabetes. , 2006, The Journal of clinical investigation.

[33]  M. Magnuson,et al.  The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. , 2006, Diabetes.

[34]  J. Grippo,et al.  Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.

[35]  C. Newgard,et al.  Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. , 1999, Diabetes.

[36]  S. Yagihashi,et al.  Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients , 2002, Diabetologia.

[37]  J. Agudo,et al.  Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance , 2003, Diabetologia.

[38]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[39]  Matschinsky Fm.  Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. , 1996 .

[40]  M. Prentki,et al.  Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. , 2000, Diabetes.

[41]  Y. Yazaki,et al.  Analysis of the Pancreatic β Cell in the Mouse with Targeted Disruption of the Pancreatic β Cell-Specific Glucokinase Gene , 1996 .

[42]  M. Coghlan,et al.  Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. , 2004, Diabetes.

[43]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.

[44]  J. Kushner,et al.  Very Slow Turnover of β-Cells in Aged Adult Mice , 2005 .